Zymeworks Common Stock Stock Market Value
| ZYME Stock | USD 12.25 0.30 2.39% |
| Symbol | Zymeworks |
Zymeworks Common Stock Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.62) | Revenue Per Share | Quarterly Revenue Growth 0.833 | Return On Assets | Return On Equity |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Zymeworks Common 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Zymeworks Common's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Zymeworks Common.
| 12/15/2024 |
| 03/15/2025 |
If you would invest 0.00 in Zymeworks Common on December 15, 2024 and sell it all today you would earn a total of 0.00 from holding Zymeworks Common Stock or generate 0.0% return on investment in Zymeworks Common over 90 days. Zymeworks Common is related to or competes with Day One, Inozyme Pharma, Zentalis Pharmaceuticals, Syndax Pharmaceuticals, Protagonist Therapeutics, Revolution Medicines, and Blueprint Medicines. Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for ... More
Zymeworks Common Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Zymeworks Common's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Zymeworks Common Stock upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0029 | |||
| Maximum Drawdown | 17.43 | |||
| Value At Risk | (6.62) | |||
| Potential Upside | 5.6 |
Zymeworks Common Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zymeworks Common's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Zymeworks Common's standard deviation. In reality, there are many statistical measures that can use Zymeworks Common historical prices to predict the future Zymeworks Common's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | 0.0708 | |||
| Total Risk Alpha | 0.4812 | |||
| Treynor Ratio | (0.09) |
Zymeworks Common Stock Backtested Returns
Zymeworks Common Stock shows Sharpe Ratio of -0.0395, which attests that the company had a -0.0395 % return per unit of risk over the last 3 months. Zymeworks Common Stock exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Zymeworks Common's Standard Deviation of 3.64, mean deviation of 2.73, and Market Risk Adjusted Performance of (0.08) to validate the risk estimate we provide. The firm maintains a market beta of 1.42, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Zymeworks Common will likely underperform. At this point, Zymeworks Common Stock has a negative expected return of -0.14%. Please make sure to check out Zymeworks Common's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Zymeworks Common Stock performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.32 |
Poor reverse predictability
Zymeworks Common Stock has poor reverse predictability. Overlapping area represents the amount of predictability between Zymeworks Common time series from 15th of December 2024 to 29th of January 2025 and 29th of January 2025 to 15th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Zymeworks Common Stock price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current Zymeworks Common price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | -0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 1.1 |
Zymeworks Common Stock lagged returns against current returns
Autocorrelation, which is Zymeworks Common stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Zymeworks Common's stock expected returns. We can calculate the autocorrelation of Zymeworks Common returns to help us make a trade decision. For example, suppose you find that Zymeworks Common has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Zymeworks Common regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Zymeworks Common stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Zymeworks Common stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Zymeworks Common stock over time.
Current vs Lagged Prices |
| Timeline |
Zymeworks Common Lagged Returns
When evaluating Zymeworks Common's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Zymeworks Common stock have on its future price. Zymeworks Common autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Zymeworks Common autocorrelation shows the relationship between Zymeworks Common stock current value and its past values and can show if there is a momentum factor associated with investing in Zymeworks Common Stock.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out Zymeworks Common Correlation, Zymeworks Common Volatility and Zymeworks Common Alpha and Beta module to complement your research on Zymeworks Common. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Zymeworks Common technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.